130 related articles for article (PubMed ID: 2650395)
21. Current status of bone marrow transplantation.
Sullivan KM
Transplant Proc; 1989 Jun; 21(3 Suppl 1):41-50. PubMed ID: 2662535
[No Abstract] [Full Text] [Related]
22. Imaging the complications of bone marrow transplantation in children.
Levine DS; Navarro OM; Chaudry G; Doyle JJ; Blaser SI
Radiographics; 2007; 27(2):307-24. PubMed ID: 17374855
[TBL] [Abstract][Full Text] [Related]
23. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
24. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
25. [Clinical aspects of bone marrow transplantation].
Schmitz N; Gassmann W; Löffler H
Ter Arkh; 1986; 58(9):18-23. PubMed ID: 3538471
[No Abstract] [Full Text] [Related]
26. Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation.
Ringdén O; Deeg HJ; Beschorner W; Slavin S
Transplant Proc; 1987 Feb; 19(1 Pt 3):2758-61. PubMed ID: 3547953
[No Abstract] [Full Text] [Related]
27. Allogeneic bone marrow transplantation: acute and late complications.
Tabbara IA
Anticancer Res; 1996; 16(2):1019-26. PubMed ID: 8687093
[TBL] [Abstract][Full Text] [Related]
28. Quantitative assessment of hematopoietic chimerism after allogeneic bone marrow transplantation has predictive value for the occurrence of irreversible graft failure and graft-vs.-host disease.
Gyger M; Baron C; Forest L; Lussier P; Lagacé F; Bissonnette I; Bélanger R; Bonny Y; Busque L; Roy DC; Perreault C
Exp Hematol; 1998 May; 26(5):426-34. PubMed ID: 9590660
[TBL] [Abstract][Full Text] [Related]
29. Kinetics of prevention of graft-versus-host disease and bone marrow rejection by ultraviolet B modulation of bone marrow inoculum.
Oluwole SF; Engelstad K; Hardy MA
Transplant Proc; 1992 Dec; 24(6):2858-9. PubMed ID: 1465974
[No Abstract] [Full Text] [Related]
30. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia.
Huss R; Deeg HJ; Gooley T; Bryant E; Leisenring W; Clift R; Buckner CD; Martin P; Storb R; Appelbaum FR
Bone Marrow Transplant; 1996 Oct; 18(4):767-76. PubMed ID: 8899193
[TBL] [Abstract][Full Text] [Related]
31. Graft-versus-host disease.
Parkman R
Annu Rev Med; 1991; 42():189-97. PubMed ID: 2035965
[TBL] [Abstract][Full Text] [Related]
32. Mixed autologous allogeneic bone marrow transplantation in rabbits.
Gratwohl A; Baldomero H; Speck B
Transplant Proc; 1989 Feb; 21(1 Pt 3):3079-81. PubMed ID: 2523172
[No Abstract] [Full Text] [Related]
33. Critical issues in bone marrow transplantation.
Storb R
Transplant Proc; 1987 Feb; 19(1 Pt 3):2774-81. PubMed ID: 3547955
[No Abstract] [Full Text] [Related]
34. Results of four different protocols for prophylaxis against graft-versus-host disease.
Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
[No Abstract] [Full Text] [Related]
35. Immunosuppression, graft-versus-host disease, and infection after bone marrow transplantation.
Kramer BS; Elfenbein GJ
J Fla Med Assoc; 1984 May; 71(5):321-8. PubMed ID: 6429272
[No Abstract] [Full Text] [Related]
36. Marrow transplant experience for children with severe aplastic anemia.
Sanders JE; Storb R; Anasetti C; Deeg HJ; Doney K; Sullivan KM; Witherspoon RP; Hansen J
Am J Pediatr Hematol Oncol; 1994 Feb; 16(1):43-9. PubMed ID: 8311172
[TBL] [Abstract][Full Text] [Related]
37. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
38. Similarity of scleroderma-like skin lesions in allogeneic and syngeneic bone marrow transplantation models.
Bos GM; Majoor GD; Slaaf DW; van de Gaar MJ; Weijmer-van Velzen JS; van Breda Vriesman PJ
Transplant Proc; 1989 Apr; 21(2):3262-3. PubMed ID: 2652812
[No Abstract] [Full Text] [Related]
39. [Graft versus host reaction and hybrid resistance in experimental models and clinical practice].
Clerici M; Villa ML; Clerici E
Boll Ist Sieroter Milan; 1988; 67(3):177-96. PubMed ID: 3072013
[TBL] [Abstract][Full Text] [Related]
40. The role of minor histocompatibility antigens in GVHD and rejection: a mini-review.
Goulmy E; Voogt P; van Els C; de Bueger M; van Rood J
Bone Marrow Transplant; 1991; 7 Suppl 1():49-51. PubMed ID: 2043886
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
